# BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

> **NCT01320280** · PHASE2 · TERMINATED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 29 (actual)

## Conditions studied

- Refractory Cancer

## Interventions

- **DRUG:** BIBW 2992 (Afatinib)

## Key facts

- **NCT ID:** NCT01320280
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** unexpectedly slow recruitment
- **Last updated:** 2022-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01320280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01320280, "BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01320280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*